Cited by 489Antifungal resistance and susceptibilityReproductive tract infections researchUrinary Tract Infections Management

Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis

Sobel, Jack D., Wiesenfeld, Harold C., Martens, Mark, Danna, Penny, Hooton, Thomas M., Rompalo, Anne, Sperling, Malcolm, Livengood, Charles +5 more·2004·New England Journal of Medicine

Abstract

BACKGROUND: No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis. METHODS: After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis. RESULTS: Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P< 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P<0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache. CONCLUSIONS: Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.

Integrity signals

Registry

Crossref · 10.1056/nejmoa033114

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Although symptom resolution is achieved in ~90% of women with RVVC who undergo at least 6 months of maintenance therapy, up to 50% will have a recurrence after the termination of maintenance therapy.

    “Although symptom resolution is achieved in ~90% of women with RVVC who undergo ⩾6 months of maintenance therapy,16,21,22 up to 50% will have a recurrence after the termination of maintenance therapy. 13”
  • A landmark RVVC treatment study using an induction regimen of fluconazole (three 150 mg doses at 72 h intervals) followed by weekly maintenance doses of 150 mg of fluconazole for 6 months was shown to reduce symptoms and recurrences.

    “A landmark RVVC treatment study using an induction regimen of fluconazole (three 150 mg doses at 72 h intervals) followed by weekly maintenance doses of 150 mg of fluconazole for 6 months was shown to reduce symptoms and recurrences. 21”
  • The mainstay of treatment for most cases of uncomplicated VVC is azole antifungals, which inhibit the fungal enzyme CYP51 and prevent accumulation of fungitoxic sterols.

    “The mainstay of treatment for most cases of uncomplicated VVC is azole antifungals, which, by inhibiting the fungal enzyme CYP51, prevent the accumulation of fungitoxic sterols [11,34].”
  • During treatment phases, relapse rates vary between 21%, 57.1%, and 71.9% at 12 months depending upon the characteristics of the therapeutic regimen used.

    “During the treatment phases, relapse rates vary between 21% (Donders et al., 2008a), 57.1% (Sobel et al., 2004), and 71.9% (Bolouri et al., 2009) at 12 months depending upon the characteristics of the therapeutic regimen used, as described in Supplementary Tables 2 and 3 .”
  • Up to 50% of women with RVVC relapsed after stopping their maintenance therapy regimen.

    “Likewise, other studies found that up to 50% of women with RVVC relapsed after stopping their maintenance therapy regimen (Sobel et al., 2004; Donders et al., 2008a) or that additional fluconazole therapy was continued for longer than 6 months due to either culture-confirmed VVC recurrence, microbiologically unconfirmed but clinically possible VVC recurrence, or due to patients’ preference to”

Cites

Flagged first, then by citations

1 of the 21 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T.-C.
Affiliations
  • Wayne State University (US)
  • University of Pittsburgh (US)
  • Hennepin County Medical Center (US)
  • University of Washington (US)
  • Johns Hopkins University (US)
  • Pfizer (United States) (US)
Venue
New England Journal of Medicine
Published
2004-08-26
Volume
351
Issue
9
Pages
876-883
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2106311471
Cited by
487
References
21
Citations by year
2026: 12 · 2025: 17 · 2024: 17 · 2023: 26 · 2022: 22 · 2021: 21 · 2020: 22 · 2019: 15 · 2018: 28 · 2017: 30 · 2016: 26 · 2015: 29 · 2014: 23 · 2013: 24 · 2012: 23
FWCI
11.43
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
Keywords
recurrent vulvovaginal candidiasis, fluconazole, maintenance therapy, Candida albicans, Candida glabrata, antifungal resistance, superinfection, recurrence prevention, clinical remission
MeSH terms
Administration, Oral, Adult, Antifungal Agents, Candida albicans, Candidiasis, Vulvovaginal, Double-Blind Method, Drug Administration Schedule, Female, Humans, Remission Induction, Time Factors, Vagina, Fluconazole, Logistic Models, Drug Resistance, Fungal, Candida glabrata, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review